• Browse
• Mi cuenta (Login)
• Inscripción (gratuita)

Pharmaceutical News

• Phase III Study Showed Rituxan In Combination With Chemotherapy Improved Progression-Fre ...
  Sun, 12 October 2008
  Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) today announced that a global Phase III study of Rituxan (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival (PFS), as assessed by investigators, in patients with previously tre ...
• Early Data Show Potential For Imatinib To Treat Life-threatening Form Of Pulmonary Arter ...
  Sun, 12 October 2008
  An early proof-of-concept study presented shows promising results for imatinib in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder.
• Boston Scientific To Release Broad Range Of Clinical Trial Data On The Performance Of TA ...
  Sun, 12 October 2008
  Boston Scientific Corporation (NYSE: BSX) announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, which runs from October 12 to 17 in Washington, D.C.
• FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 ...
  Sun, 12 October 2008
  Takeda Pharmaceutical Company Limited (Takeda) announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification that the U.S. Food and Drug Administration (FDA) will not be able to complete its review of the alogliptin New Drug Applica ...
• A Forecast Insight Report Into The Antidiabetics Market - Switching To New Molecule Anti ...
  Sat, 11 October 2008
  Research and Markets has announced the addition of the Forecast Insight: Antidiabetics - Switching to New Molecule Antidiabetics Drives Market Growth report to their offering. The antidiabetics market is expected to reach 29 billion, across the seven major markets, by 2017.
• Izard Nobel LLP Announces Class Action Lawsuit Against Biovail Corporation
  Sat, 11 October 2008
  The law firm of Izard Nobel LLP, which has significant experience representing investors in prosecuting claims of securities fraud, announces that a lawsuit seeking class action status has been filed in the United States District Court for the Southern District of New York on behalf of those who purchased Biovail Corporation ...
• Counterfeit Medicines - Report Urges No Compromise And No Concession Of Principle In Mai ...
  Sat, 11 October 2008
  EFPIA, the voice of the research-based pharmaceutical industry in Europe, welcomes the release of the Europe Economics report on 'Safe Medicines Through Parallel Trade'i.
• Drug Information Association 7th Annual Electronic Submissions Conference: ECTD
  Sat, 11 October 2008
  The Drug Information Association's (DIA's) 7th Annual Electronic Submissions Conference: eCTD (November 5-7; San Diego, CA) will focus on the practical experience gained, lessons learned, and resulting best practices as the pharma industry moves to a fully electronic drug application submission paradigm.
• Media Statement From Servier: High Court Of Justice Judgment Awarding Damges To Apotex
  Sat, 11 October 2008
  Servier is disappointed by the decision of the English High Court (Mr Justice Norris) to award damages to Apotex of GBP17.5 million in the case of Les Laboratoires Servier vs Apotex Inc. Servier is currently considering whether to appeal the Judgment. However, Servier acknowledges that Mr Justice Norris's Jud ...
• SCOLR Pharma Announces Completion Of Patient Enrollment And Dosing For Pivotal Clinical ...
  Sat, 11 October 2008
  SCOLR Pharma, Inc. (Amex: DDD) announced the completion of patient enrollment and dosing for the third of its three pivotal trials to evaluate the safety and efficacy of its formulation of 12-hour extended-release (ER) ibuprofen for the over-the-counter (OTC) market. The Company expects to report top- ...